[{"id":"e2ee4ae6-e5bb-4363-a70b-cff99327284d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05207787","created_at":"2022-01-26T13:53:55.881Z","updated_at":"2024-07-02T16:35:46.723Z","phase":"Phase 1/2","brief_title":"Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05207787","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" PD-L1 • RET","pipe":"","alterations":" ","tags":["PD-L1 • RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e resencatinib (HS-10365)"],"overall_status":"Recruiting","enrollment":" Enrollment 306","initiation":"Initiation: 11/09/2021","start_date":" 11/09/2021","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-06-01"}]